Jennifer S. Childs

1.1k total citations
46 papers, 812 citations indexed

About

Jennifer S. Childs is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jennifer S. Childs has authored 46 papers receiving a total of 812 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Immunology, 27 papers in Oncology and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jennifer S. Childs's work include Immunotherapy and Immune Responses (31 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Jennifer S. Childs is often cited by papers focused on Immunotherapy and Immune Responses (31 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Jennifer S. Childs collaborates with scholars based in United States, South Korea and Canada. Jennifer S. Childs's co-authors include Mary L. Disis, Doreen M. Higgins, Yushe Dang, Lupe G. Salazar, Andrew L. Coveler, James Waisman, Hailing Lu, Patricia A. Fintak, Corazon dela Rosa and Ekram Gad and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Jennifer S. Childs

45 papers receiving 792 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer S. Childs United States	14	581	529	232	160	48	46	812
Olga Blomberg Netherlands	9	303 0.5×	293 0.6×	181 0.8×	140 0.9×	33 0.7×	9	583
Brian J. Czerniecki United States	12	413 0.7×	342 0.6×	180 0.8×	68 0.4×	69 1.4×	23	615
Yongxiang Yan China	8	332 0.6×	356 0.7×	203 0.9×	70 0.4×	59 1.2×	12	619
Jens Pahl Germany	12	565 1.0×	418 0.8×	187 0.8×	54 0.3×	90 1.9×	20	794
Benjamin M. Larimer United States	12	293 0.5×	454 0.9×	121 0.5×	260 1.6×	54 1.1×	32	673
Francesca I. Okoye United States	6	645 1.1×	398 0.8×	197 0.8×	141 0.9×	20 0.4×	8	762
Cinzia Remondo Italy	12	479 0.8×	517 1.0×	216 0.9×	53 0.3×	65 1.4×	16	795
Luna Minute Spain	12	529 0.9×	504 1.0×	194 0.8×	32 0.2×	60 1.3×	16	858
James M. Leatherman United States	13	443 0.8×	461 0.9×	271 1.2×	36 0.2×	93 1.9×	26	814
Pia M. Challita-Eid United States	10	255 0.4×	279 0.5×	142 0.6×	80 0.5×	59 1.2×	18	556

Countries citing papers authored by Jennifer S. Childs

Since Specialization

Citations

This map shows the geographic impact of Jennifer S. Childs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer S. Childs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer S. Childs more than expected).

Fields of papers citing papers by Jennifer S. Childs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer S. Childs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer S. Childs. The network helps show where Jennifer S. Childs may publish in the future.

Co-authorship network of co-authors of Jennifer S. Childs

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer S. Childs. A scholar is included among the top collaborators of Jennifer S. Childs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer S. Childs. Jennifer S. Childs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gwin, William R., Lupe G. Salazar, James Y. Dai, et al.. (2025). A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer. Vaccines. 13(2). 117–117. 1 indexed citations

Liao, John B., William R. Gwin, Yushe Dang, et al.. (2024). Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer. Gynecologic Oncology. 191. 74–79. 1 indexed citations

Disis, Mary L., Yushe Dang, Andrew L. Coveler, et al.. (2023). A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer. Clinical Cancer Research. 29(17). 3362–3371. 5 indexed citations

Gwin, William R., Jennifer S. Childs, Andrew L. Coveler, et al.. (2023). A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.. Journal of Clinical Oncology. 41(16_suppl). TPS636–TPS636. 3 indexed citations

Disis, Mary L., Ying Liu, Sasha E. Stanton, et al.. (2022). 546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer. Regular and Young Investigator Award Abstracts. A571–A571. 10 indexed citations

Cecil, Denise L., John B. Liao, Yushe Dang, et al.. (2021). Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses. Clinical Cancer Research. 27(23). 6405–6412. 11 indexed citations

Liao, John B., William R. Gwin, Renata R. Urban, et al.. (2021). Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. Journal for ImmunoTherapy of Cancer. 9(9). e003122–e003122. 17 indexed citations

Gwin, William R., et al.. (2018). Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.. Journal of Clinical Oncology. 36(15_suppl). TPS5613–TPS5613. 2 indexed citations

Liao, John B., Ron E. Swensen, Leonard D’Amico, et al.. (2017). Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecologic Oncology. 144(3). 480–485. 13 indexed citations

10.

Stanton, Sasha E., Janet F. Eary, David A. Mankoff, et al.. (2016). Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. Journal for ImmunoTherapy of Cancer. 4(1). 27–27. 23 indexed citations

11.

Dang, Yushe, et al.. (2015). The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent. Clinical Cancer Research. 22(9). 2207–2216. 20 indexed citations

12.

Cecil, Denise L., Gregory E. Holt, Kyong Hwa Park, et al.. (2014). Elimination of IL-10–Inducing T-Helper Epitopes from an IGFBP-2 Vaccine Ensures Potent Antitumor Activity. Cancer Research. 74(10). 2710–2718. 38 indexed citations

13.

Disis, Mary L., Yushe Dang, Andrew L. Coveler, et al.. (2013). HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunology Immunotherapy. 63(2). 101–109. 31 indexed citations

14.

Childs, Jennifer S., et al.. (2011). OT1-02-10: Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients.. Cancer Research. 71(24_Supplement). OT1–2. 1 indexed citations

15.

Dang, Yushe, Lupe G. Salazar, Andrew L. Coveler, et al.. (2009). Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine (41.3). The Journal of Immunology. 182(Supplement_1). 41.3–41.3. 1 indexed citations

16.

Goodell, Vivian, James Waisman, Lupe G. Salazar, et al.. (2008). Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Molecular Cancer Therapeutics. 7(3). 449–454. 42 indexed citations

17.

Coveler, Andrew L., Vivian Goodell, Lupe G. Salazar, et al.. (2008). Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Research and Treatment. 113(1). 95–100. 11 indexed citations

18.

Salazar, Lupe G., Ron E. Swensen, Andrew L. Coveler, et al.. (2008). Phase I study of intraperitoneal (IP) denileukin diftitox in patients with advanced ovarian cancer (OC). Journal of Clinical Oncology. 26(15_suppl). 3036–3036. 2 indexed citations

19.

Dang, Yushe, Keith L. Knutson, Corazon dela Rosa, et al.. (2006). Tumor antigen specific T cell expansion is greatly facilitated by in vivo priming.. Cancer Research. 66. 1308–1308.

20.

Childs, Jennifer S., et al.. (1998). Clinical supervision for cancer nurses: BACUP's experience. European Journal of Oncology Nursing. 2(1). 62–63. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact